Canine adenovirus type 2 (CAV2) has become an attractive vector for gene therapy because of its non-pathogenicity and the lack of pre-existing neutralizing antibodies against this virus in the human population. Additionally, this vector has been proposed as a conditionally replicative adenovirus agent under the control of an osteocalcin promoter for evaluation in a syngeneic, immunocompetent canine model with spontaneous osteosarcoma. In this study, a CAV2 vector labelled with the fluorescent capsid fusion protein IX-enhanced green fluorescent protein (pIX-EGFP) was developed. Expression of the fluorescent fusion-protein label in infected cells with proper nuclear localization, and incorporation into virions, could be detected. The labelled virions could be visualized by fluorescence microscopy; this was applicable to the tracking of CAV2 infection, as well as localizing the distribution of the vector in tissues. Expression of pIX-EGFP could be exploited to detect the replication and spread of CAV2. These results indicate that pIX can serve as a platform for incorporation of heterologous proteins in the context of a canine adenovirus xenotype. It is believed that capsid-labelled CAV2 has utility for vector-development studies and for monitoring CAV2-based oncolytic adenovirus replication.
INTRODUCTIONAdenoviral vectors have been widely implemented to deliver genes for the purpose of therapy (Curiel & Douglas, 2002). The attractiveness of this vector system includes the well-documented knowledge encompassing its biology and pathology (Shenk, 1996), relative safety associated with the virus and ease in upscaling vector production. More recently, manipulation of the viral genome by recombinant techniques has yielded cell-specific vectors founded on various concepts, including transductional (Wickham, 2003), transcriptional (Miller & Whelan, 1997;Nettelbeck et al., 2000) and translational (Ahmed et al., 2003) targeting. Furthermore, enhanced safety, long-term transgene expression and greater cloning capacity have resulted from the ability to generate helper-dependent adenoviral vectors that are completely devoid of native viral genes (Kochanek et al., 2001). Despite these advances in adenoviral vector engineering, two key unresolved issues remain. First, preexisting humoral and cellular immunity against human adenoviruses, especially serotypes 2 and 5 (Ad2 and Ad5) on which most current adenoviral vectors are based, can have profound effects on initial vector administration and, increasingly, on repeat applications (Crystal et al., 1995;Zabner et al., 1994). Second, replication-competent adenovirus contamination of recombinant viral stocks poses a health risk, even in the case of gutless vectors (Lochmuller et al., 1994).Vector systems based on other, less pathogenic human adenovirus serotypes and various xenotypes have been proposed to overcome these concerns (Both, 2004;Gao et al., 2003; Rasmussen et al., 1999;Reddy et al., 1999). Among the diverse approaches, a canine adenovirus type 2 (CAV2) vector demonstrated...